Search
naxitamab-gqgk (Danyelza)
Indications:
- in combination with GM-CSF, for treatment of children >= 1 year of age & adults with relapsed or refractory high-risk neuroblastoma in bone or bone marrow with prior response to therapy
Contraindications:
- pregnancy
Dosage:
- 3 mg/kg/day (up to 150 mg/day) IV infusion after dilution on days 1,3 & 5 of each treatment cycle.
- treatment cycles repeated every 4 weeks until complete or partial response, followed by 5 additional cycles every 4 weeks
- subsequent cycles may be repeated every 8 weeks
40 mg/10 mL injection
Monitor:
- blood pressure during & after infusion
Adverse effects:
- most common (> 25%)
- infusion-related reaction,pain, tachycardia, vomiting, cough, nausea, diarrhea, decreased appetite, hypertension, fatigue, erythema multiforme, peripheral neuropathy, urticaria, pyrexia, headache, injection site reaction, edema, anxiety,localized edema, & irritability
- hypertension
- serious infusion reactions
- cardiac arrest, anaphylaxis, hypotension, bronchospasm, & stridor
- neurotoxicity
- severe neuropathic pain
- transverse myelitis
- reversible posterior leukoencephalopathy syndrome
Mechanism of action:
- GD2-binding monoclonal antibody
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- HIGHLIGHTS OF PRESCRIBING INFORMATION
https://labeling.ymabs.com/danyelza